Monthly Archives: August 2021

A plant that ‘cannot die’ reveals its genetic secrets – The Independent

Posted: August 5, 2021 at 2:39 am

The longest-lived leaves in the plant kingdom can be found only in the harsh, hyperarid desert that crosses the boundary between southern Angola and northern Namibia.

A desert is not, of course, the most hospitable place for living things to grow, let alone leafy greens, but the Namib Desert the worlds oldest, with parts receiving less than 2 inches of precipitation a year is where Welwitschia calls home.

In Afrikaans, the plant is named tweeblaarkanniedood, which means two leaves that cannot die. The naming is apt: Welwitschia grows only two leaves and continuously in a lifetime that can last millenniums.

Most plants develop a leaf, and thats it, says Andrew Leitch, a plant geneticist at Queen Mary University of London. This plant can live thousands of years, and it never stops growing. When it does stop growing, its dead.

Some of the largest plants are believed to be more than 3,000 years old, with two leaves steadily growing since the beginning of the Iron Age, when the Phoenician alphabet was invented and David was crowned King of Israel.

By some accounts, Welwitschia is not much to look at. Its two fibrous leaves, buffeted by dry desert winds and fed on by thirsty animals, become shredded and curled over time, giving Welwitschia a distinctly octopus-like look. One 19th-century director of Kew Gardens remarked, It is out of the question the most wonderful plant ever brought to this country and one of the ugliest.

But since it was first discovered, Welwitschia has captivated biologists including Charles Darwin and botanist Friedrich Welwitsch, after whom the plant is named; it is said that when Welwitsch first came across the plant in 1859, he could do nothing but kneel down on the burning soil and gaze at it, half in fear lest a touch should prove it a figment of the imagination.

When we see that the plant can live in this environment for so long and preserve its DNA and proteins, I feel like we can find hints for how to improve agriculture

In a study published recently in Nature Communications, researchers report some of the genetic secrets behind Welwitschias unique shape, extreme longevity and profound resilience.

Jim Leebens-Mack, a plant biologist at the University of Georgia not involved in the study, says it gives us a foundation for better understanding how Welwitschia does all the crazy stuff that it does.

The Welwitschia genome reflects the plants arid and nutrient-poor surroundings. And its genetic history seems to correspond with environmental history.

Approximately 86 million years ago, after a mistake in cell division, the entire Welwitschia genome doubled during a time of increased aridity and prolonged drought in the region and possibly the formation of the Namib Desert itself, says Tao Wan, a botanist at the Fairy Lake Botanical Garden in Shenzhen, China, and lead author of the study. He says that extreme stress is often associated with such genome duplication events.

Leitch, a co-author of the study, adds that duplicated genes are also released from their original functions, potentially taking on new ones.

However, having more genetic material comes with a cost, Wan says.

The most basic activity for life is DNA replication, he says, so if you have a big genome, it is really energy-consuming to maintain life, especially in such a harsh environment.

To make matters worse, a large amount of Welwitschias genome is junk self-replicating DNA sequences called retrotransposons.

Now that junk needs to be replicated, repaired, Leitch says.

The researchers detected a burst of retrotransposons activity 1 to 2 million years ago, most likely because of increased temperature stress. But to counteract this, the Welwitschia genome underwent widespread epigenetic changes that silenced the junk DNA through a process called DNA methylation.

This process, along with other selective forces, drastically pared down the size and energetic maintenance cost of Welwitschias duplicated library of DNA, Wan says, giving it a very efficient, low-cost genome.

The plants leaves pour out of its base

(Getty/iStock)

The study also found that Welwitschia had other genetic tweaks hidden up its leaves.

The average plant leaf grows from the plants apexes, or the tippy-tops of its stem and branches. But Welwitschias original growing tip dies, and leaves instead pour out of a vulnerable area of the plants anatomy called the basal meristem, which supplies fresh cells to the growing plant, Wan says. A large number of copies or increased activity of some genes involved with efficient metabolism, cell growth and stress resilience in this area may help it continue to grow under extreme environmental stress. In a warming world, the genetic lessons that Welwitschia has to offer may help humans breed hardier, less thirsty crops.

When we see that the plant is able to live in this environment for so long and preserve its DNA and its proteins, I really feel like we can find hints for how to improve agriculture, Leebens-Mack says.

The study also underscores the importance of curiosity-driven research. When you encounter two leaves growing in a desert against all odds, kneel down in the burning soil and take a closer look.

From weird things, you discover weird things that help you understand things that you didnt know you didnt understand, Leitch says.

This article originally appeared in The New York Times

Here is the original post:
A plant that 'cannot die' reveals its genetic secrets - The Independent

Posted in Georgia Stem Cells | Comments Off on A plant that ‘cannot die’ reveals its genetic secrets – The Independent

SucSEED Indovation starts their HealthTech Investment with AyuRythm, a Wellness Platform. – Techstory

Posted: August 5, 2021 at 2:37 am

AyuRythm (HourOnEarth Creative Solutions Pvt Ltd), has secured an undisclosed amount in Fundraise SucSEED Indovation Fund and other several marquee Angel investors as part of its Seed round. AyuRythm is your hyper-personalized digital companion for holistic wellness, with a blend of modern technologies with the ancient science of health assessment and care. Leveraging a simple 30-second pulse analysis (Nadi Pariksha) by placing fingers on smartphone cameras, AyuRythm aims to redefine holistic wellness via personalized recommendations based on an individuals mind, body, and metabolic imbalance.

AyuRythm provides an affordable, instantaneous, complete, personalized, wellness solution on the hands of consumers by integrating cutting edge digital Nadi pariksha (pulse analysis) into mobile phones. Unlike current offerings which focus on expensive devices for physicians, AyuRythm allows consumers to use existing smartphones or wearables. It provides real-time assessment and just-in-time wellness recommendations. AyuRythms assessment and recommendation engines are certified by leading institutions, like SVYASA, HCG, Niraamaya Retreat, Dr Vaidyas, as well as by many individual experts.

Pandemic has reinforced consumers interest in holistic wellness to boost immunity, reduce stress and stay well using ancient methods like Ayurveda and yoga. During the second wave of the pandemic, AyuRythms activation rate increased by 60% and the install base reached ~100,000.

AyuRythm Team

Abhilesh Gupta, the Founder and CEO of AyuRythm said, People are unique and so are their wellness needs. Our aha moment came when we realized more than 90% of consumers are looking for sustainable wellness solutions beyond aggressive exercise like running, weight-lifting and cycling. The overwhelming response from the young adult population during the past few months has certainly validated our hypotheses and opened up exciting possibilities ahead, globally.

He further added that The seed funding we raised from SucSEED Indovation Fund and such established Angel Investors will help us enhance our product and technology capabilities, strengthening our team and accelerate growth.

Speaking on why they have invested in AyuRythm, VVSN Raju Partner of SucSEED Indovation Fund, said, As the pandemic continues, people have become more heedful towards their well-being and there is a need for sustainable personalized wellness. AyuRythm provides digitized real-time assessments by merging Ayurveda with AI algorithm to recommend proactive solutions. They address the underlying causes and treatments of the ailments and stress-related issues which can be accessible and analyzed on smart devices and wearables. As the wellness and healthcare segment is growing fast, AyuRythm provides digitized end-to-end holistic wellness experience.

About the market Potential in this space: Ayurveda (and its allied industry like yoga) industry is on the cusp of high growth and change. It is predicted to be about $15Bn by 2022 and growing at 16% CAGR approximately. The product market is $11Bn and service is around $4Bn. According to the PWC report, about 77% of Indian households have used at least 1 Ayurveda product every year. The Worldwide Ayurveda product market is close to $10Bn growing again at 16%. Yoga products like yoga mats are close to $2Bn in the US alone.

https://www.ayurythm.com

Founded by Ram, Sandeep and Abhilesh, who saw the need for a sustainable and personalized wellness solution for 90% of the population, enabled by everyday devices like smartphones and wearables. Using signal processing and patent-pending algorithms, the startup assesses the users mind, body and metabolic imbalance, and personalizes the diet and activities to help users achieve and maintain their wellness state.

Abhilesh Gupta, Founder and CEO at AyuRythm- A seasoned executive with 25 years of accomplishments in different sectors, geographies, and areas of business. A diehard health and wellness enthusiast.

Ramanath Padmanabhan, Founder & CPO at AyuRythm Seasoned product management executive and a leader with decades of experience in building and scaling health and wellness solutions globally.

Sandeep Acharya, Founder and COO at AyuRythm An Engineer and MBA, having more than a decade of experience in customer data analytics, with expertise in areas of customer intelligence, statistical modelling, and end-to-end analytics landscape setup, in the banking and healthcare sector.

Original post:
SucSEED Indovation starts their HealthTech Investment with AyuRythm, a Wellness Platform. - Techstory

Posted in HCG Diet | Comments Off on SucSEED Indovation starts their HealthTech Investment with AyuRythm, a Wellness Platform. – Techstory

Exicure, Inc. to Present at the BTIG Virtual Biotechnology Conference – Business Wire

Posted: August 5, 2021 at 2:33 am

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today announced that CEO David Giljohann will present at the BTIG Virtual Biotechnology Conference on Monday, August 9, 2021 at 2:30pm ET. Exicure will also host 1x1 investor meetings during the conference.

BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative with interest.

About Exicure, Inc.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN a lipid-nanoparticle SNAbased therapeutic candidate, for the intrathecal treatment of Friedreichs ataxia (FA). Exicures therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2 clinical trial in patients with advanced solid tumors. Exicure is based in Chicago, IL and in Cambridge, MA.

View original post here:
Exicure, Inc. to Present at the BTIG Virtual Biotechnology Conference - Business Wire

Posted in Biotechnology | Comments Off on Exicure, Inc. to Present at the BTIG Virtual Biotechnology Conference – Business Wire

Anavex Life Sciences to Participate in the BTIG Virtual Biotechnology Conference 2021 – Yahoo Finance

Posted: August 5, 2021 at 2:33 am

NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimers disease, Parkinsons disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a fireside chat in the BTIG Virtual Biotechnology Conference 2021 on Tuesday, August 10, 2021 at 9:30 a.m. EDT.

Webcast for the conference will be available in the Investors section under "Events" of the Anavex corporate website at http://www.anavex.com. To listen to the live event, please contact a BTIG representative with interest.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimers disease, Parkinsons disease, Rett syndrome and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavexs lead drug candidate, ANAVEX2-73 (blarcamesine), successfully completed a Phase 2a clinical trial for Alzheimers disease and recently a Phase 2 proof-of-concept study in Parkinsons disease dementia and a Phase 2 study in adult patients with Rett syndrome. ANAVEX2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimers disease. ANAVEX2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinsons Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX2-73 for the treatment of Parkinsons disease. ANAVEX3-71, which targets sigma-1 and muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimers disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at http://www.anavex.com. You can also connect with the company on Twitter, Facebook, Instagram and LinkedIn.

Story continues

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Companys most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For Further Information:

Anavex Life Sciences Corp.Research & Business DevelopmentToll-free: 1-844-689-3939Email: info@anavex.com

Investors:Andrew J. BarwickiInvestor RelationsTel: 516-662-9461Email: andrew@barwicki.com

Continued here:
Anavex Life Sciences to Participate in the BTIG Virtual Biotechnology Conference 2021 - Yahoo Finance

Posted in Biotechnology | Comments Off on Anavex Life Sciences to Participate in the BTIG Virtual Biotechnology Conference 2021 – Yahoo Finance

Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference – Yahoo Finance

Posted: August 5, 2021 at 2:33 am

PHILADELPHIA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 9, 2021 at 9:00 a.m. E.T.

A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.

About Amicus Therapeutics Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the companys website at http://www.amicusrx.com, and follow us on Twitter and LinkedIn.

CONTACT:

Investors:Andrew FaughnanExecutive Director, Investor Relationsafaughnan@amicusrx.com(609) 662-3809

Media:Diana MooreHead of Global Corporate Communicationsdmoore@amicusrx.com(609) 662-5079

FOLDG

See the original post here:
Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference - Yahoo Finance

Posted in Biotechnology | Comments Off on Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference – Yahoo Finance

Agenus to Participate in the BTIG Virtual Biotechnology Conference 2021 – Yahoo Finance

Posted: August 5, 2021 at 2:33 am

LEXINGTON, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Jennifer Buell, PhD, President and COO of Agenus, will participate in a fireside chat at the BTIG Biotechnology Conference 2021 on Monday, August 9, 2021 from 3:00 p.m. to 3:25 p.m. ET.

BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative.

About AgenusAgenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies through its MiNK Therapeutics subsidiary (formerly AgenTus Therapeutics), adjuvants, and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit http://www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.

ContactAgenus Investor RelationsJan Medina, CFAAgenus781-674-4490Jan.Medina@agenusbio.com

Agenus Media RelationsKimberly HaKKH Advisors917-291-5744kimberly.ha@kkhadvisors.com

The rest is here:
Agenus to Participate in the BTIG Virtual Biotechnology Conference 2021 - Yahoo Finance

Posted in Biotechnology | Comments Off on Agenus to Participate in the BTIG Virtual Biotechnology Conference 2021 – Yahoo Finance

BTIG to Host the BTIG Virtual Biotechnology Conference on August 9-10, 2021 – Business Wire

Posted: August 5, 2021 at 2:33 am

NEW YORK--(BUSINESS WIRE)--BTIG announced today that the BTIG Virtual Biotechnology Conference will take place on Monday, August 9th and Tuesday, August 10, 2021. The event will be hosted by the BTIG Biotechnology Research team - Robert Bert Hazlett, Tom Shrader, PhD, CFA, Justin Zelin and Yun Zhong, PhD, as well as BTIG Healthcare Strategy and Franchise Sales Specialists Michael Karmiol and Mikhail Keyserman, CMT, CFTe.

With more than 120 established and emerging biotechnology companies participating, corporate management teams will engage with BTIGs institutional investors for fireside chats, thematic panel discussions and one-on-one meetings. We are thrilled to host an extraordinary group of industry leaders at our annual biotech conference this month, noted Dan Wychulis, Managing Director and Head of U.S. Strategy and Franchise Sales at BTIG. The corporate management teams attending are leading some of the most innovative public and private companies. Their commitment to develop life-changing technology and care solutions is making a difference in healthcare. We look forward to engaging discussions and an opportunity for investors to gain insights on the successes, challenges and investment objectives of these remarkable biotechnology companies.

Topics for the thematic panel discussions will include Cell Therapy: Transforming Immune Cells to Mainstream Cancer Treatments, Reemergence and Development of Psychedelics in Mental Health Conditions, Disrupting the Standard of Care of Immune-Mediated Diseases, The Best Path into the CNS - A Rundown of Gene Therapy, ASO and BBB-Shuttle Approaches, ADCs: Whats Exciting in Novel Linkers, Targets and Payloads?, Solid Tumors: Driving Lymphocytes Harder vs. Recruiting Other Immune Cells, The Role of Lipid Metabolism in Neurodegeneration, Neurodegeneration Biomarkers and Is a Cure on the Table for Type 1 Diabetes?.

For more information about the conference, email info@btig.com. Please note that participants must be pre-registered to attend. To access BTIG insights, contact a firm representative or log in to http://www.btigresearch.com.

The conference is being produced by BTIGs Corporate Access program which hosts client events across the consumer, energy and infrastructure, financials, healthcare, real estate as well as technology, media, and telecommunications sectors.

About BTIG

BTIG is a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global footprint and more than 650 employees, BTIG, LLC and its affiliates operate out of 19 cities throughout the U.S., and in Europe, Asia and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs and fixed income, currency and commodities (futures, interest rates, credit, and convertible and preferred securities). The firms core capabilities include global execution, portfolio, electronic and outsource trading, transition management, investment banking, prime brokerage, capital introduction, corporate access, research and strategy, commission management and more. Disclaimer: https://www.btig.com/disclaimer.

To learn more about BTIG, visit http://www.btig.com.

Link:
BTIG to Host the BTIG Virtual Biotechnology Conference on August 9-10, 2021 - Business Wire

Posted in Biotechnology | Comments Off on BTIG to Host the BTIG Virtual Biotechnology Conference on August 9-10, 2021 – Business Wire

Gain Therapeutics to Present at the BTIG Virtual Biotechnology Conference – Yahoo Finance

Posted: August 5, 2021 at 2:33 am

BETHESDA, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (Gain), a biotechnology company focused on redefining drug discovery by identifying and optimizing novel allosteric binding sites on proteins responsible for neurodegenerative diseases and lysosomal storage disorders, today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present a corporate overview at the BTIG Virtual Biotechnology Conference being held on August 9 10.

BTIG Virtual Biotechnology Conference

Date:

Monday, August 9TH

Time:

11:30 to 11:55 a.m. ET

Presenter:

Eric Richman, Chief Executive Officer

Please contact your BTIG representative to listen to the live event and schedule a virtual one-on-one meeting with Gains management team during the conference.

About BTIG Virtual Biotechnology ConferenceThe annual August conference will be held virtually. BTIG expects to host more than 120 corporate management teams throughout the two-day, private event which includes thematic panels featuring key opinion leaders, fireside chats, and one-on-one meetings.

For further information, please visit: http://www.BTIG.com

About Gain Therapeutics, Inc.Gain Therapeutics, Inc. is redefining drug discovery with its SEE-Tx target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain was established in 2017 with the support of its founders and institutional investors. It has been awarded funding support from The Michael J. Fox Foundation for Parkinsons Research (MJFF) and The Silverstein Foundation for Parkinsons with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA, a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc.

Story continues

For more information, visit https://www.gaintherapeutics.com/

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements." In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of these terms and other comparable terminology. These statements are not historical facts but instead represent the Company's belief regarding future results, many of which, by their nature, are inherently uncertain and outside the Company's control. It is possible that actual results, including with respect to any financial forecast or the possibility of any future regulatory approval or filing, may differ materially from those anticipated in these forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Companys Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, as filed with the Securities and Exchange Commission on May 5 2021, as well as other documents that may be filed by the Company from time to time.

New risks and uncertainties arise over time, and it is not possible for us to predict all such factors or how they may affect us. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. We are under no duty to update any of these forward-looking statements after the date of this earnings release to conform these statements to actual results or revised expectations. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this earnings release.

Investor Contact:Daniel FerryLifeSci Advisors+1 617-430-7576daniel@lifesciadvisors.com

Originally posted here:
Gain Therapeutics to Present at the BTIG Virtual Biotechnology Conference - Yahoo Finance

Posted in Biotechnology | Comments Off on Gain Therapeutics to Present at the BTIG Virtual Biotechnology Conference – Yahoo Finance

The Global Biotechnology Reagents Market is expected to grow by USD 32.11 billion during 2021-2025, progressing at a CAGR of 7.39% during the forecast…

Posted: August 5, 2021 at 2:33 am

New York, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Biotechnology Reagents Market 2021-2025" - https://www.reportlinker.com/p04821786/?utm_source=GNW 39% during the forecast period. Our report on the biotechnology reagents market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the high usage of biotechnology reagents in diagnostic and therapeutic applications and increasing R&D investments by federal agencies and biotechnology firms. In addition, the high usage of biotechnology reagents in diagnostic and therapeutic applications is anticipated to boost the growth of the market as well.The biotechnology reagents market analysis includes the technology segment and geographic landscape.

The biotechnology reagents market is segmented as below:By Technology Chromatography In-vitro diagnostics Polymerase chain reaction Cell culture Others

By Geography North America Europe Asia ROW

This study identifies the presence of high throughput and novel technologies as one of the prime reasons driving the biotechnology reagents market growth during the next few years.

The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on biotechnology reagents market covers the following areas: Biotechnology reagents market sizing Biotechnology reagents market forecast Biotechnology reagents market industry analysis

This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading biotechnology reagents market vendors that include Abbott Laboratories, Agilent Technologies Inc., Becton, Dickinson and Co., Bio Rad Laboratories, Inc, Danaher Corp., F. Hoffmann La Roche Ltd., General Electric Co., Merck KGaA, PerkinElmer Inc., and Thermo Fisher Scientific Inc. Also, the biotechnology reagents market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavios market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.Read the full report: https://www.reportlinker.com/p04821786/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

See the article here:
The Global Biotechnology Reagents Market is expected to grow by USD 32.11 billion during 2021-2025, progressing at a CAGR of 7.39% during the forecast...

Posted in Biotechnology | Comments Off on The Global Biotechnology Reagents Market is expected to grow by USD 32.11 billion during 2021-2025, progressing at a CAGR of 7.39% during the forecast…

MannKind Corporation to Participate in the BTIG Virtual Biotechnology Conference 2021 – Yahoo Finance

Posted: August 5, 2021 at 2:33 am

WESTLAKE VILLAGE, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat in the BTIG Virtual Biotechnology Conference 2021 on Tuesday, August 10, 2021 at 12:30 PM (ET).

BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative with interest.

About MannKind CorporationMannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza (insulin human) Inhalation Powder, the Companys first FDA-approved product and the only inhaled ultra-rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil where it is commercialized by the Companys partner Biomm SA. MannKind was established in 1991, and is headquartered in Westlake Village, Calif., with a manufacturing and R&D facility in Danbury, Conn. The Company also employs field sales and medical representatives across the U.S. Please visit http://www.mannkindcorp.com to learn more.

MANNKIND CONTACT:Rose Alinaya, Investor Relations Phone: (818) 661-5000 Email: ir@mannkindcorp.com

Read the rest here:
MannKind Corporation to Participate in the BTIG Virtual Biotechnology Conference 2021 - Yahoo Finance

Posted in Biotechnology | Comments Off on MannKind Corporation to Participate in the BTIG Virtual Biotechnology Conference 2021 – Yahoo Finance